Guidant
This article was originally published in The Gray Sheet
Executive Summary
U.S. shipments of the Discovery and Meridian next-generation pacemaker families are scheduled to begin May 5, following receipt of FDA approval April 30, the firm says. Approved via premarket approval application supplement to Guidant's Vigor pacemaker, the device families include single- and dual-chamber models with adaptive-rate pacing and advanced diagnostics. The devices incorporate Quick Start, Quick Check and Quick Notes features, designed to allow clinicians "to easily and quickly perform a comprehensive set of automatic tests and follow-up device operations," and provide a printout summarizing data needed for informed patient management, Guidant explains. The Discovery line also has the ability to store and display "diagnostic-quality atrial and ventricular electrograms simultaneously." The devices debuted in Europe in mid-March
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.